Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
The diagnostic algorithm should always begin with a monoclonal protein screen to assess for
AL amyloidosis. If AL amyloidosis is suspected, initiate laboratory testing to assess
for monoclonal protein production and evidence of vital organ involvement or
dysfunction. In AL amyloidosis, free lambda or free
kappa levels are elevated.
